Anders Gülfe

Medicine & Life Sciences

1. Rheumatoid Arthritis 100%
2. Arthritis 72%
3. Tumor Necrosis Factor Inhibitors 67%
4. Sweden 53%
5. Rheumatic Diseases 52%
6. Tumor Necrosis Factor-alpha 47%
7. Psoriatic Arthritis 46%
8. Observational Studies 42%
9. Quality-Adjusted Life Years 31%
10. Biological Products 29%
11. Cohort Studies 27%
12. Spondylarthritis 24%
13. Health Care Outcome Assessment 23%
14. Surgical Wound Infection 22%
15. Therapeutics 22%
16. Joints 17%
17. Hand 15%
18. Abatacept 14%
19. tocilizumab 14%
20. Methotrexate 13%
21. Antirheumatic Agents 13%
22. Sick Leave 12%
23. Health 11%
24. Synovial Fluid 11%
25. Patient Reported Outcome Measures 11%
26. Rituximab 10%
27. Orthopedic Procedures 10%
28. Knee Replacement Arthroplasties 10%
29. Rheumatology 10%
30. Confidence Intervals 9%
31. Pharmaceutical Preparations 9%
32. Hip 9%
33. Survival 8%
34. Cartilage Oligomeric Matrix Protein 8%
35. Cartilage 8%
36. Lymphoma 8%
37. Ankylosing Spondylitis 8%
38. Infections 7%
39. Cost-Benefit Analysis 7%
40. Etanercept 7%
41. Aggrecans 7%
42. Cardiovascular Diseases 7%
43. C-Reactive Protein 7%
44. Prospective Studies 7%
45. Biomarkers 6%
46. Incidence 6%
47. Integrin-Binding Sialoprotein 6%
48. Bone and Bones 5%
49. Baths 5%
50. Odds Ratio 5%